---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-062722"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:51:37.137355+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma's YUPELRI approved by China's NMPA; $7.5M milestone triggered

## Summary
- China's NMPA approved YUPELRI (revefenacin) as first once-daily nebulized LAMA for COPD maintenance.
- Approval triggers $7.5M milestone from Viatris, expected Q3 2025; eligible for up to $37.5M in sales milestones and 14-20% tiered royalties.
- Viatris responsible for all development/commercialization; Theravance incurs no commercial costs in China.
- Theravance cash $131M (Mar 31), plus $225M from TRELEGY royalty sale and up to $150M near-term TRELEGY milestones.
- Theravance nearing completion of enrollment in open-label portion of CYPRESS study of ampreloxetine for nOH in MSA.

## SEC filing metadata
- accession: 0001104659-25-062722
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465925062722/0001104659-25-062722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465925062722/tm2519052d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-062722
- JSON: https://secwatch.observer/filing/0001104659-25-062722.json
- Plain text: https://secwatch.observer/filing/0001104659-25-062722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.